FDA advisory panel reviews Moderna's mRNA flu vaccine for approval.
An FDA advisory committee is evaluating Moderna's mFlusiva, the first mRNA-based flu vaccine, for use in people 50 and older. A study of 40,000 people showed the vaccine reduced flu cases by about 27% compared to a standard vaccine, with no safety concerns reported. The meeting follows an earlier dispute where a former FDA official blocked the application, citing concerns about study design.
3
Divergence score
4 outlets covered it, splitting into 3 framing camps across 2 bias groups.
3 camps
2 bias groups
Market signalBETA
The spectrum · how 4 outlets placed this story
LeftCenterRight
AP News
Washington Times
NY Post
Reuters
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
The split, in one line
Coverage is largely uniform; outlets differ only in headline emphasis. AP and Washington Times lead with the mRNA technology angle, NY Post highlights historic shot, and Reuters frames around panel scrutiny.
How each outlet covered it
Only the right is covering this
One side of the spectrum has stayed silent. That absence is itself a signal.
0
LEFT OUTLETS
0 of 4 outlets covering this story sit on that side of the spectrum.
0LEFT OUTLETS
THE RIGHT
“First-of-its-kind flu vaccine could be coming as FDA panel weighs historic shot”NYP NY Post RIGHT
DOWN THE MIDDLE
“Moderna's mRNA flu vaccine faces FDA advisory panel scrutiny” · AP News, Reuters
+Hide the full sourcingSee how all 4 outlets put it
Tracked claims from across the political spectrum
Fact ledger
Corroborated
Disputed